@article{805816a2f7444a39bf9fe3412690dd40,
title = "Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control",
abstract = "Background: In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear. Methods: SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized controlled trial that compared the effects of intensive (target <120 mm Hg) and standard (target <140 mm Hg) SBP control in 9361 older adults with high blood pressure at increased risk of cardiovascular disease. The primary outcome was a composite of cardiovascular disease events. All-cause death and incident chronic kidney disease were secondary outcomes. This post hoc analysis examined whether the effects of the SBP intervention differed by baseline DBP. Results: Mean baseline SBP and DBP were 139.7±15.6 and 78.1±11.9 mm Hg, respectively. Regardless of the randomized treatment, baseline DBP had a U-shaped association with the hazard of the primary cardiovascular disease outcome. However, the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline DBP level (P for interaction=0.83). The primary outcome hazard ratio for intensive versus standard treatment was 0.78 (95% confidence interval, 0.57-1.07) in the lowest DBP quintile (mean baseline DBP, 61±5 mm Hg) and 0.74 (95% confidence interval, 0.61-0.90) in the upper 4 DBP quintiles (mean baseline DBP, 82±9 mm Hg), with an interaction P value of 0.78. Results were similar for all-cause death and kidney events. Conclusions: Low baseline DBP was associated with increased risk of cardiovascular disease events, but there was no evidence that the benefit of the intensive SBP lowering differed by baseline DBP.",
keywords = "Blood pressure, Hypertension, Randomized controlled trial",
author = "{SPRINT Research Group} and Srinivasan Beddhu and Chertow, {Glenn M.} and Cheung, {Alfred K.} and Cushman, {William C.} and Mahboob Rahman and Tom Greene and Guo Wei and Campbell, {Ruth C.} and Margaret Conroy and Freedman, {Barry I.} and William Haley and Edward Horwitz and Dalane Kitzman and James Lash and Vasilios Papademetriou and Roberto Pisoni and Erik Riessen and Clive Rosendorff and Watnick, {Suzanne G.} and Jeffrey Whittle and Whelton, {Paul K.}",
note = "Funding Information: All components of the SPRINT study protocol were designed and implemented by the investigators. The investigative team collected, analyzed, and interpreted the data. All aspects of manuscript writing and revision were carried out by the coauthors. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the US Department of Veterans Affairs, or the US government. For a full list of contributors to SPRINT, please see the supplementary material and acknowledgment list at https://www.sprinttrial.org/public/dsp-Science.cfm. We also acknowledge the support from the following Clinical and Translational Science Awards funded by National Center for Advancing Translational Sciences: Case Western Reserve University, UL1TR000439; Ohio State Univer- Funding Information: sity, UL1RR025755; University of Pennsylvania, UL1RR024134 and UL1TR000003; Boston University, UL1RR025771; Stanford University, UL1TR000093; Tufts, UL1RR025752, UL1TR000073, and UL1TR001064; University of Illinois, UL1TR000050; University of Pittsburgh, UL1TR000005; UT Southwestern, 9U54TR000017-06; University of Utah, UL-1TR000105-05; Vanderbilt University, UL1 TR000445; George Washington University, UL1TR000075; University of California, Davis, UL1 TR000002; University of Florida, UL1 TR000064; University of Michigan, UL1TR000433; and Tulane University, P30GM103337 Center for Biomedical Research Excellence Award National Institute of General Medical Sciences. This work is also supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK091437 and R21 DK106574) and the University of Utah Study Design and Biostatistics Center (funded in part from the Public Health Services research grants UL1-RR025764 and C06-RR11234 from the National Center for Research Resources). Funding Information: SPRINT is funded with federal funds from the National Institutes of Health, including the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke, under contracts HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HH-SN268200900049C and Inter-Agency Agreement A-HL-13-002-001. It was also supported in part with resources and use of facilities through the Department of Veterans Affairs. The SPRINT Investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals International, Inc. Publisher Copyright: {\textcopyright} 2018 American Heart Association, Inc.",
year = "2018",
doi = "10.1161/CIRCULATIONAHA.117.030848",
language = "English",
volume = "137",
pages = "134--143",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",
}